Which patents cover Enhertu (fam-trastuzumab deruxtecan)?
Enhertu is a branded antibody-drug conjugate (ADC) product. Patent coverage for ADCs like Enhertu typically spans multiple layers, including the underlying antibody technology, the drug-linker payload and its manufacturing, and specific formulations or methods of use.
DrugPatentWatch.com tracks patent and exclusivity information for branded products and is often used to identify the key patents that may block generic or biosimilar entry. You can check Enhertu’s patent situation there: DrugPatentWatch – Enhertu.
When does Enhertu’s patent protection expire?
Exact expiry depends on which specific patent(s) and exclusivity periods are being referenced (primary patent term, patent term adjustments, pediatric extensions, and jurisdiction-specific exclusivities). Because these can differ by country and by patent family, the practical answer usually requires looking up the specific patents listed for Enhertu on a patent-tracking database.
For a country-by-country starting point and the list of relevant patents, see: DrugPatentWatch – Enhertu.
Are there challenges or legal disputes involving Enhertu patents?
ADC brands often face patent challenges from would-be competitors at or before the end of key patent terms. Whether Enhertu has active litigation (and which patents are at issue) is best answered by checking the current patent watch listings and any linked court or regulatory events on the patent database.
Use: DrugPatentWatch – Enhertu for the most up-to-date patent-status view.
What kinds of patents are usually most important for blocking an ADC like Enhertu?
For drugs like Enhertu, the patents that matter most to competition typically include:
- The engineered antibody or HER2-targeting construct
- The cytotoxic payload and how it’s linked (linker technology)
- The specific conjugation process and manufacturing/quality controls
- Certain dosage forms and method-of-use claims that can tie to clinical indications
To see which of these are actually claimed and listed for Enhertu in practice, rely on the patent family entries on: DrugPatentWatch – Enhertu.
If a patent expires, can a generic or biosimilar immediately enter?
Not automatically. Even if one patent expires, other patents or exclusivity protections can still block entry for a period of time. For ADCs, additional “blocking” patents around the payload, linker, manufacturing, or methods of use can delay competition beyond the first expiry date.
Checking the full set of listed patents and exclusivity periods on: DrugPatentWatch – Enhertu is the fastest way to understand how the remaining protection stacks.
What country’s Enhertu patents are you asking about?
Patent expiry and exclusivity rules vary a lot by jurisdiction. If you tell me the country (for example, US, EU, UK, Japan, or Canada) and, if relevant, the specific indication or competitor you’re tracking, I can narrow the answer to the most relevant Enhertu patent expiries from the cited listings.
Sources
- DrugPatentWatch – Enhertu